Form 4: Artiva Officer's Stock Withholding for Taxes

Artiva Biotherapeutics' Chief Tech Operations Officer, Christopher Horan, reported share dispositions to cover tax obligations from restricted stock unit vesting.

Summary

• Christopher Horan, Chief Tech Operations Officer at Artiva Biotherapeutics, Inc. (ARTV), reported changes in beneficial ownership.
• On May 15, 2025, 1,341 shares of common stock were disposed of at $2.13 per share.
• On August 15, 2025, an additional 3,577 shares of common stock were disposed of at $2.75 per share.
• These dispositions were not discretionary sales but represent shares withheld by Artiva Biotherapeutics to satisfy income tax obligations related to the vesting of restricted stock unit awards.
• Following these transactions, Christopher Horan beneficially owns 80,082 shares of common stock directly.

Sentiment

Score: 7

Explanation: The filing reports routine insider transactions related to tax withholding on RSU vesting, which is a neutral to slightly positive event as it indicates equity compensation vesting. It does not suggest any negative sentiment from the insider.

Positives

• The dispositions are for tax withholding purposes, indicating the vesting of restricted stock units, which is a positive for the employee as it represents earned compensation.
• The officer continues to hold a significant number of shares (80,082), aligning his interests with shareholders.

Negatives

• A reduction in direct share ownership, although for tax purposes, still decreases the officer's total holdings.

Future Outlook

This filing does not contain forward-looking statements or guidance, as it is a report of past insider transactions.

Management Comments

• The dispositions represent shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of restricted stock unit awards.

Industry Context

Form 4 filings are routine disclosures for publicly traded companies, reflecting changes in insider ownership. These specific transactions, related to tax withholding on RSU vesting, are common in the biotechnology industry and across various sectors, indicating standard compensation practices rather than a change in strategic direction.

Comparison to Industry Standards

• These transactions are standard 'sell to cover' events for restricted stock unit vesting, a common practice across all industries, including biotechnology. They do not reflect discretionary sales or a change in management's confidence in the company.
• Comparable companies often see similar Form 4 filings when executive compensation includes equity awards.

Stakeholder Impact

• Shareholders: No direct impact on company operations or strategy. The transactions are routine and related to executive compensation.
• Employees: Reflects standard equity compensation practices for executives.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to tax withholding on restricted stock unit vesting. It does not indicate any discretionary buying or selling by the officer that would suggest a change in their outlook on the company's prospects. Therefore, it provides no new information to alter an existing investment thesis, warranting a 'hold' recommendation based solely on this filing.

Keywords

Artiva Biotherapeutics, ARTV, SEC Form 4, Insider Trading, Stock Ownership, Restricted Stock Units, Tax Withholding, Christopher Horan, Biotechnology